These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 38957786)

  • 1. CAR T cells redirected to B7-H3 for pediatric solid tumors: Current status and future perspectives.
    Epperly R; Gottschalk S; DeRenzo C
    EJC Paediatr Oncol; 2024 Jun; 3():. PubMed ID: 38957786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors.
    Majzner RG; Theruvath JL; Nellan A; Heitzeneder S; Cui Y; Mount CW; Rietberg SP; Linde MH; Xu P; Rota C; Sotillo E; Labanieh L; Lee DW; Orentas RJ; Dimitrov DS; Zhu Z; Croix BS; Delaidelli A; Sekunova A; Bonvini E; Mitra SS; Quezado MM; Majeti R; Monje M; Sorensen PHB; Maris JM; Mackall CL
    Clin Cancer Res; 2019 Apr; 25(8):2560-2574. PubMed ID: 30655315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B7-H3-targeted CAR-T cell therapy for solid tumors.
    Li G; Wang H; Wu H; Chen J
    Int Rev Immunol; 2022; 41(6):625-637. PubMed ID: 35855615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Directing B7-H3 chimeric antigen receptor T cell homing through IL-8 induces potent antitumor activity against pediatric sarcoma.
    Lake JA; Woods E; Hoffmeyer E; Schaller KL; Cruz-Cruz J; Fernandez J; Tufa D; Kooiman B; Hall SC; Jones D; Hayashi M; Verneris MR
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 39043604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting B7-H3-A Novel Strategy for the Design of Anticancer Agents for Extracranial Pediatric Solid Tumors Treatment.
    Rasic P; Jeremic M; Jeremic R; Dusanovic Pjevic M; Rasic M; Djuricic SM; Milickovic M; Vukadin M; Mijovic T; Savic D
    Molecules; 2023 Apr; 28(8):. PubMed ID: 37110590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell-surface antigen profiling of pediatric brain tumors: B7-H3 is consistently expressed and can be targeted via local or systemic CAR T-cell delivery.
    Haydar D; Houke H; Chiang J; Yi Z; Odé Z; Caldwell K; Zhu X; Mercer KS; Stripay JL; Shaw TI; Vogel P; DeRenzo C; Baker SJ; Roussel MF; Gottschalk S; Krenciute G
    Neuro Oncol; 2021 Jun; 23(6):999-1011. PubMed ID: 33320196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A high-content screen of FDA approved drugs to enhance CAR T cell function: ingenol-3-angelate improves B7-H3-CAR T cell activity by upregulating B7-H3 on the target cell surface via PKCα activation.
    Lee HW; O'Reilly C; Beckett AN; Currier DG; Chen T; DeRenzo C
    J Exp Clin Cancer Res; 2024 Apr; 43(1):97. PubMed ID: 38561833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3-Specific CAR T Cells in Solid Tumors.
    Lei X; Ou Z; Yang Z; Zhong J; Zhu Y; Tian J; Wu J; Deng H; Lin X; Peng Y; Li B; He L; Tu Z; Chen W; Li Q; Liu N; Zhang H; Wang Z; Fang Z; Yamada T; Lv X; Tian T; Pan G; Wu F; Xiao L; Zhang L; Cai T; Wang X; Tannous BA; Li J; Kontos F; Ferrone S; Fan S
    Clin Cancer Res; 2021 Jul; 27(13):3757-3771. PubMed ID: 33811153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B7-H3 in Brain Malignancies: Immunology and Immunotherapy.
    Guo X; Chang M; Wang Y; Xing B; Ma W
    Int J Biol Sci; 2023; 19(12):3762-3780. PubMed ID: 37564196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel Orthotopic Implantation Technique for Osteosarcoma Produces Spontaneous Metastases and Illustrates Dose-Dependent Efficacy of B7-H3-CAR T Cells.
    Talbot LJ; Chabot A; Funk A; Nguyen P; Wagner J; Ross A; Tillman H; Davidoff A; Gottschalk S; DeRenzo C
    Front Immunol; 2021; 12():691741. PubMed ID: 34211478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B7-H3-Targeting Chimeric Antigen Receptors Epstein-Barr Virus-specific T Cells Provides a Tumor Agnostic Off-The-Shelf Therapy Against B7-H3-positive Solid Tumors.
    Yeo SP; Kua L; Tan JW; Lim JK; Wong FH; Santos MD; Poh CM; Goh AX; Koh XY; Zhou X; Rajarethinam R; Chen Q; Her Z; Horak ID; Low L; Tan KW
    Cancer Res Commun; 2024 Jun; 4(6):1410-1429. PubMed ID: 38717140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B7-H3 specific T cells with chimeric antigen receptor and decoy PD-1 receptors eradicate established solid human tumors in mouse models.
    Huang B; Luo L; Wang J; He B; Feng R; Xian N; Zhang Q; Chen L; Huang G
    Oncoimmunology; 2020; 9(1):1684127. PubMed ID: 32002297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting osteosarcoma with canine B7-H3 CAR T cells and impact of CXCR2 Co-expression on functional activity.
    Cao JW; Lake J; Impastato R; Chow L; Perez L; Chubb L; Kurihara J; Verneris MR; Dow S
    Cancer Immunol Immunother; 2024 Mar; 73(5):77. PubMed ID: 38554158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel anti-B7-H3 chimeric antigen receptor from a single-chain antibody library for immunotherapy of solid cancers.
    Birley K; Leboreiro-Babe C; Rota EM; Buschhaus M; Gavriil A; Vitali A; Alonso-Ferrero M; Hopwood L; Parienti L; Ferry G; Flutter B; Himoudi N; Chester K; Anderson J
    Mol Ther Oncolytics; 2022 Sep; 26():429-443. PubMed ID: 36159778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preconditioning of radiotherapy enhances efficacy of B7-H3-CAR-T in treating solid tumor models.
    Wang T; Zhang K; You F; Ma R; Yang N; Tian S; An G; Yang L
    Life Sci; 2023 Oct; 331():122024. PubMed ID: 37574043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD276-CAR T cells and Dual-CAR T cells targeting CD276/FGFR4 promote rhabdomyosarcoma clearance in orthotopic mouse models.
    Timpanaro A; Piccand C; Dzhumashev D; Anton-Joseph S; Robbi A; Moser J; Rössler J; Bernasconi M
    J Exp Clin Cancer Res; 2023 Nov; 42(1):293. PubMed ID: 37924157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. STRIvE-02: A First-in-Human Phase I Study of Systemically Administered B7-H3 Chimeric Antigen Receptor T Cells for Patients With Relapsed/Refractory Solid Tumors.
    Pinto N; Albert CM; Taylor MR; Ullom HB; Wilson AL; Huang W; Wendler J; Pattabhi S; Seidel K; Brown C; Gustafson JA; Rawlings-Rhea SD; Cheeney SHE; Burleigh K; Gustafson HH; Orentas RJ; Vitanza NA; Gardner RA; Jensen MC; Park JR
    J Clin Oncol; 2024 Sep; ():JCO2302229. PubMed ID: 39255444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric Antigen Receptor T cell Therapy and the Immunosuppressive Tumor Microenvironment in Pediatric Sarcoma.
    Terry RL; Meyran D; Fleuren EDG; Mayoh C; Zhu J; Omer N; Ziegler DS; Haber M; Darcy PK; Trapani JA; Neeson PJ; Ekert PG
    Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells.
    Du H; Hirabayashi K; Ahn S; Kren NP; Montgomery SA; Wang X; Tiruthani K; Mirlekar B; Michaud D; Greene K; Herrera SG; Xu Y; Sun C; Chen Y; Ma X; Ferrone CR; Pylayeva-Gupta Y; Yeh JJ; Liu R; Savoldo B; Ferrone S; Dotti G
    Cancer Cell; 2019 Feb; 35(2):221-237.e8. PubMed ID: 30753824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B7-H3-Targeted CAR-T Cells Exhibit Potent Antitumor Effects on Hematologic and Solid Tumors.
    Zhang Z; Jiang C; Liu Z; Yang M; Tang X; Wang Y; Zheng M; Huang J; Zhong K; Zhao S; Tang M; Zhou T; Yang H; Guo G; Zhou L; Xu J; Tong A
    Mol Ther Oncolytics; 2020 Jun; 17():180-189. PubMed ID: 32346608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.